Local cytokine treatment of HPV16-associated tumours results in inhibition of their lung metastases

Clinical and Experimental Metastasis

Volumn 18, Issue 7, 2000, Pages 581-587

  Mikyšková, Romana ^a   Bubeník, Jan ^a   Mendoza, Luis ^a   Vonka, Vladimír ^b   Šmahel, Michal ^b   Šímová, Jana ^a   Jandlová, Táňa ^a  

^a INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

^b INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

Dendritic cells; HPV16; IL 12; IL 2; Lung metastasis

Indexed keywords

INTERLEUKIN 12; INTERLEUKIN 2; PLASMID DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; FEMALE; LUNG METASTASIS; METASTASIS INHIBITION; MINIMAL RESIDUAL DISEASE; MOUSE; NONHUMAN; ONCOGENE H RAS; SUBCUTANEOUS TISSUE TUMOR; TUMOR RECURRENCE; TUMOR VOLUME; VIRUS TRANSFORMATION; WART VIRUS;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, CD86; ANTINEOPLASTIC AGENTS; CARCINOMA; CELL DIVISION; CELL LINE, TRANSFORMED; FEMALE; HISTOCOMPATIBILITY ANTIGENS; INTERLEUKIN-12; INTERLEUKIN-2; LUNG NEOPLASMS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; PAPILLOMAVIRUS INFECTIONS; TUMOR VIRUS INFECTIONS;

EID: 0034793550     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011987206008     Document Type: Article

References (32)

1. Vaccination for treatment of tumours: A critical comment
2. Gene transfer for immunotherapy of cancer
3. Genetically engineered dendritic cell-based cancer vaccines
4. Metastatic MHC class I-negative mouse cells derived by transformation with human papilomavirus type 16
5. Interleuken 2 gene therapy of mice carrying tumours induced by HPV 16
6. Cytokine gene-modified vaccines in the therapy of cancer
7. The interleukin-12/interleukin-12-receptor system: Role in normal and pathologic immune responses
8. Solubilized tumour-associated antigens of methylcholanthrene-induced mouse sarcomas. Comparative studies by in vitro sensitization of lymph node cells, macrophage electrophoretic mobility assay and transplantation test
9. Genetically modified tumour vaccines: Insertion of the IL-2 gene downregulates tumorigenicity more efficiently than insertion of the CD80 gene
10. Cloned dendritic cell can present exogenous antigens on both MHC class I and class II molecules
11. T-cell growth factor: Parameters of production and a quantitative microassay for activity
12. Tumour inhibitory effects of TCGF/IL-2/-containing preparations
13. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens
14. Adhesion mediated by LFA-1 is required for efficient IL-12-induced NK and NKT cell cytotoxicity
15. +αβT cells in the lungs of euthymic and athymic mice
16. + αβT cells activated by IL-12 as a major effector in inhibition of experimental tumor metastasis
17. In situ cytokine therapy: Redistribution of clonally expanded T cells
18. Antitumour and antimetastatic activity of IL-12 against murine tumors
19. Effect of in vivo IL-12 administration on murine tumor cell growth
20. Fibroblasts genetically engineered to secrete IL-12 can supress tumor growth and induce antitumor immunity to a murine melanoma in vivo
21. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production
22. Preclinical development of IL-12 as an anticancer drug: Comparison to IL-2
23. Interleukin-12(IL-12) immunotherapy of experimental bladder cancer
24. + tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon γ
25. Interleukin-12 activates NK cells for IFN-γ-dependent and NKT cells for IFN-γ-independent antimetastatic activity
26. Impact of the number of treatments courses on the clinical response of patients who receive high-dose bolus interleukin-2
27. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: Longterm survival update
28. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993
29. Inhibition of experimental lung metastasis of murine colon carcinoma cells depends on the amount of interleukin-2 secreted from the transduced cells
30. Local and systemic effects during interleukin-2 therapy of mouse mammary tumors
31. Influence of the administration schedule on the therapeutic effect of interleukin-2
32. Administration of recombinant interleukin 12 prevents outgrowth of tumor cells metastazising spontaneously to lung and lymph nodes